

**REMARKS**

**I. STATUS OF THE CLAIMS AND FORMAL MATTERS**

Claims 1-2, 5-7, and 12-16 were pending in the present application. Claims 15 and 16 are cancelled, and claim 1 has been amended to recite that the angiodependent disease is psoriasis. No new matter has been introduced.

In addition, Applicants wish to remind the Examiner of the Change in Power of Attorney and Correspondence Address filed August 25, 2008. Accordingly, kindly direct all communications in this application to Frommer Lawrence & Haug LLP, 745 Fifth Avenue, New York, NY 10151.

**II. THE REJECTIONS UNDER 35 U.S.C. § 112, FIRST PARAGRAPH, ARE OVERCOME**

Claims 1-2, 5-7 and 12-16 are rejected under 35 U.S.C. § 112, first paragraph, because the specification while being enabling for psoriasis, by administering 2,5-dihydroxybenzenesulfonic acid, allegedly does not reasonably provide enablement for the treatment of any angiodependent disease. The rejection is respectfully traversed.

Solely to expedite prosecution, claim 1 has been amended to recite that the angiodependent disease is psoriasis. The Office Action acknowledges that the specification is enabling for psoriasis by administering 2,5-dihydroxybenzenesulfonic acid (Office Action, page 2).

Accordingly, reconsideration and withdrawal of the rejections under 35 U.S.C. § 112, first paragraph, are respectfully requested.

**REQUEST FOR INTERVIEW**

If any issue remains as an impediment to allowance, prior to issuance of any paper other than a Notice of Allowance, an interview is respectfully requested with the Examiner, and the Examiner is respectfully requested to contact the undersigned to arrange a mutually convenient time and manner for such an interview.

**CONCLUSION**

Early and favorable consideration of the application on the merits, and early Allowance of the application are earnestly solicited.

The Commissioner is authorized to charge any fee occasioned by this paper, or credit any overpayment in fees, to Deposit Account No. 50-0320.

Respectfully submitted,  
FROMMER LAWRENCE & HAUG LLP

By: /Kathleen N. Ehrhard/  
Sandra Kuzmich, Ph.D.  
Reg. No. 46,117  
Kathleen N. Ehrhard, Ph.D.  
Reg. No. 55,144  
Tel.: (212) 588-0800